ORIGINAL ARTICLE
Expressions of EZH2 and NOTCH3 pathway in osteosarcoma and their roles in osteosarcoma stem cells
1
Department of Pathology, General Hospital of Southern Theater Command, Guangzhou, People’s Republic of China
2
Department of Pathology, The Second affiliated hospital, Army Medical University, Chongqing, People’s Republic of China
Submission date: 2022-09-27
Acceptance date: 2022-10-27
Publication date: 2023-03-06
Corresponding author
Zhuocai Wang
Zhuocai Wang Department of Pathology General Hospital of Southern Theater Command No. 111, Liuhua Avenue Guangzhou, Guangdong People’s Republic of China, 510010
Zhuocai Wang Department of Pathology General Hospital of Southern Theater Command No. 111, Liuhua Avenue Guangzhou, Guangdong People’s Republic of China, 510010
Pol J Pathol 2022;73(4):343-351
KEYWORDS
TOPICS
ABSTRACT
Osteosarcoma (OS) is the most common malignant bone tumour; however, the underlying mechanisms are mainly unknown. Enhancer of zeste homologue 2 (EZH2) and NOTCH pathway are important molecular signals related to carcinogenesis and tumour progression, but they are not fully understand in OS.
Enhancer of zeste homologue 2, Notch3, HES1, and Nanog were detected on OS samples and statistically analysed. Expressions of these genes were investigate, and stem-like phenotype was verified in OS cells.
This study found that higher EZH2 expression, Notch3 pathway, or Nanog were associated with tumour relapse and metastasis and a significantly shorter survival time. Moreover, the Notch3 pathway was activated in osteosarcoma stem cells. Enhancer of zeste homologue 2 overexpression could activate the Notch3 pathway and increase HES1 expression, leading to upregulated stem cell-related gene expression and self-renewal of OS cells.
Our study demonstrates that EZH2, Notch3, and Nanog are important prognostic factors. Enhancer of zeste homologue 2 could maintain the self-renewal of OS cells, where the Notch3 pathway activation may be involved.
Enhancer of zeste homologue 2, Notch3, HES1, and Nanog were detected on OS samples and statistically analysed. Expressions of these genes were investigate, and stem-like phenotype was verified in OS cells.
This study found that higher EZH2 expression, Notch3 pathway, or Nanog were associated with tumour relapse and metastasis and a significantly shorter survival time. Moreover, the Notch3 pathway was activated in osteosarcoma stem cells. Enhancer of zeste homologue 2 overexpression could activate the Notch3 pathway and increase HES1 expression, leading to upregulated stem cell-related gene expression and self-renewal of OS cells.
Our study demonstrates that EZH2, Notch3, and Nanog are important prognostic factors. Enhancer of zeste homologue 2 could maintain the self-renewal of OS cells, where the Notch3 pathway activation may be involved.
REFERENCES (23)
1.
Li YQ, Laterra J. Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res 2012; 72: 576-580.
2.
Vaz AP, Ponnusamy MP, Batra SK. Cancer stem cells and therapeutic targets: an emerging field for cancer treatment. Drug Deliv and Transl Res 2012; 3: 113-120.
3.
Gibbs CP, Levings PP, Ghivizzani SC. Evidence for the osteosarcoma stem cell. Curr Orthop Pract 2011; 22: 322-326.
4.
Liu B, Ma W, Jha RK, et al. Cancer stem cells in osteosarcoma: recent progress and perspective. Acta Oncol 2011; 50: 1142-1150.
5.
Tsang DP, Cheng AS. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol 2011; 26: 19-27.
6.
Wen Y, Cai J, Hou Y, et al. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target. Oncotarget 2017; 8: 37974-37990.
7.
Lv YF, Yan GN, Meng G, et al. Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma. Sci Rep 2015; 5: 12999.
8.
Sun RR, Shen J, Gao Y, et al. Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential. Oncotarget 2016; 7: 38333-38346.
9.
Gonzalez ME, Moore HM, Li X, et al. EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc Natl Acad Sci 2014; 111: 3098-3103.
10.
Chen S, Lee BH, Bae Y. Notch signaling in skeletal stem cells. Calcif Tissue Int 2013; 94: 68-77.
11.
Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 2011; 11: 338-351.
12.
Takebe N, Nguyen D, Yang SX. Targeting Notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther 2014; 141: 140-149.
13.
Tao J, Jiang MM, Jiang L, et al. Notch activation as a driver of osteogenic sarcoma. Cancer Cell 2014; 26: 390-401.
14.
Wang L, Jin FC, Qin A, et al. Targeting Notch1 signaling pathway positively affects the sensitivity of osteosarcoma to cisplatin by regulating the expression and/or activity of Caspase family. Mol Cancer 2014; 13: 139.
15.
Yu L, Fan ZF, Fang S, et al. Cisplatin selects for stem-like cells in osteosarcoma by activating notch signaling. Oncotarget 2016; 7: 33055-33068.
16.
Tang XF, Cao Y, Peng DB, et al. Overexpression of notch3 is associated with metastasis and poor prognosis in osteosarcoma patients. Cancer Manag Res 2019; 11: 547-559.
17.
Huang YS, Dai HZ, Guo QN. TSSC3 overexpression reduces stemness and induces apoptosis of osteosarcoma tumor-initiating cells. Apoptosis 2012; 17: 749-761.
18.
Yan GN, Yang L, Lv YF, et al. Endothelial cells promote stem-like phenotype of glioma cells through activating the Hedgehog pathway. J Pathol 2014; 234: 11-22.
19.
Yan GN, Lv YF, Guo QN. Advances in osteosarcoma stem cell research and opportunities for novel therapeutic targets. Cancer Lett 2016; 370: 268-274.
20.
Basu-Roy U, Basilico C, Mansukhani A. Perspectives on cancer stem cells in osteosarcoma. Cancer Lett 2013; 338: 158-167.
21.
Zieba JT, Chen HY, Lee BH, et al. Notch signaling in skeletal development, homeostasis and pathogenesis. Biomolecules 2020; 10: 332.
22.
Zhang QY, Lu CJ, Fang T, et al. Notch3 functions as a regulator of cell self-renewal by interacting with the b-catenin pathway in hepatocellular carcinoma. Oncotarget 2015; 6: 3669-3679.
23.
Choy L, Hagenbeek TJ, Solon M, et al. Constitutive NOTCH3 signaling promotes the growth of basal breast cancers. Cancer Res 2017; 77: 1439-1452.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
